Evidence and Identity VerificationKey Findings

What usage claims can FST 344 currently support?

Can indicate specifications in the catalog and research directions to be verified, but cannot yet give definite human or animal efficacy claims. No. Gene delivery enables tissue expression of related proteins, which differs from direct exposure to vial proteins and formulations, and cannot replace each other.

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

No. Gene delivery causes tissue to express related proteins, which is different from the exposure and formulation of directly administered vial proteins, and cannot substitute for each other. This page is a collection of usage-oriented positive data, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately marked.

Identity / formulation must be verified

Qualified direct in vivo main literature has not yet been screened

No. Gene delivery causes tissue to express related proteins, which is different from the exposure and formulation of directly administered vial proteins, and cannot substitute for each other.

See common questions about this product ↓

References

Supplement background3 articles · not counted among in vivo main literature

The following information is used to explain mechanisms, material identity, or evidence boundaries and cannot replace direct in vivo validation of the same product, formulation, and use.

Study hierarchy according to design2017 · Historical basic researchREF. 01

What questions are answered by FST344 gene delivery studies?

Research Findings

Increased muscle proportion, decreased body fat proportion.[1] ↗

Study Design

Transgenic pig; FST344 gene expression

Scope & Limitations

Gene expression experiments, not injection of bottled FST344 protein.

View the Article Title and Full Citation＋

The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs.

Chang F, Fang R, Wang M, Zhao X, Chang W, Zhang Z, Li N, Meng Q.

Transgenic Research · Volume and issue year 2017
First published 2016-10-27 · PMID 27787698
DOI 10.1007/s11248-016-9985-x

Supplementary Background · Not counted as the main literature in the bodyPubMed ↗Journal Article ↗
Human Study2017 · Historical basic researchREF. 02

What form of intervention is used in studies related to FST344 expression?

Research Findings

Some walking and histological indicators improved, supporting FS344 gene therapy development.[2] ↗

Study Design

6 patients with inclusion body myositis; AAV gene therapy.

Scope & Limitations

Combined exercise, small sample; cannot be converted into efficacy evidence for protein injection.

View the Article Title and Full Citation＋

Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK.

Molecular therapy : the journal of the American Society of Gene Therapy · Volume/Issue Year 2017
First published 2017-03-06 · PMID 28279643
DOI 10.1016/j.ymthe.2017.02.015

Supplementary Background · Not counted as the main literature in the bodyPubMed ↗Journal Article ↗
Human Study2015 · Historical basic researchREF. 03

Why can FST344 gene therapy not be equated with bottled protein?

Research Findings

Some patients showed improvements in 6-minute walk test and histological indicators.[3] ↗

Study Design

6 patients with Becker muscular dystrophy; gene therapy Phase I/IIa.

Scope & Limitations

Vector-mediated gene delivery, completely different from lyophilized protein injection.

View the Article Title and Full Citation＋

A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK.

Molecular therapy : the journal of the American Society of Gene Therapy · Volume/Issue Year 2015
First published on 2014-10-17 · PMID 25322757
DOI 10.1038/mt.2014.200

Supplementary Background · Not counted as the main literature in the bodyPubMed ↗Journal Article ↗

Direct in vivo primary literature has not been included in this round; research status is mentioned above.

Common issues and corresponding evidence

Does FST344 gene therapy validate bottled FST344 protein?＋

No. Gene delivery causes tissue to express related proteins, which is different from the exposure and formulation of directly administered vial proteins, and cannot substitute for each other.[1] ↗ [2] ↗ [3] ↗

FST 344 Why aren’t 3–5 efficacy papers listed?＋

At this stage, no sufficient qualified original studies have been screened that simultaneously correspond to commercial identity, main research purpose, and intervention form. Papers with similar names, single components, or other purposes cannot be used to supplement the data.

Current status of data / procurement verification, not efficacy conclusions.
What materials are needed when reviewing FST 344 study materials?＋

The full name, CAS or sequence, modifications/salt form, component ratio, source, and SKU batch COA should first be verified, then compared item by item with the paper materials.

Current status of data / procurement verification, not efficacy conclusions.

FST 344

Return to catalog specifications and batch file verification entry.

↗